# Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome

> **NCT02879578** · PHASE2 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 155 (actual)

## Conditions studied

- Tourette Syndrome

## Interventions

- **DRUG:** Valbenazine

## Key facts

- **NCT ID:** NCT02879578
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-25
- **Primary completion:** 2017-11-01
- **Final completion:** 2017-11-01
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2021-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02879578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02879578, "Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02879578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*